Lidocaine patch 5% for acute pain management

摘要

THE RECOMMENDED APPROACH to the man agement of acute pain is multimodal analgesia, whereby combinations of two or more analgesics with different underlying mechanisms of action produce better pain relief at lower doses than would be possible with a single analgesic. The underlying rationale for this approach is that lower doses result in fewer or less severe adverse effects. The lidocaine patch 5% (lidoderm; Endo Pharmaceuticals, Chadds Ford, PA) was approved by the US Food and Drug Administration for treatment of the persistent neuropathic pain syndrome, postherpetic neuralgia, which can occur after an episode of herpes zoster ("shingles"). The ease and simplicity of patch administration has led to its use as a component of multimodal analgesic plans for some acute pain states as well.